公司荣誉与行业认可 - 公司荣获Frost & Sullivan 2025年亚太地区技术创新领导力奖 表彰其在集成智能药物发现行业的卓越成就 [2] - 该奖项是Frost & Sullivan最高荣誉 认可公司在临床前研发中推动变革性效率的突出表现 [2] - 公司在战略制定与执行方面表现突出 在严格的基准测试中脱颖而出 [3] 技术创新与平台优势 - 公司通过多模态人工智能与广泛湿实验室验证结合 建立行业最多功能发现平台之一 [4] - AI驱动药物发现平台包含V-Scepter、V-Orb和V-Mantle三大模块 结合预测建模、物理模拟和生成式AI [5] - V-Scepter提供生物系统自动化参数化功能 支持小分子和肽类包括非经典氨基酸 [9] - V-Orb包含物理驱动建模 专有FEP计算套件优化非共价/共价结合剂及生物制剂 [9] - V-Mantle具备生成式AI能力 包括蛋白质大语言模型和抗体工程工作流 [9] 平台性能与客户成果 - 平台支持超过50家全球客户的150多个项目 实现发现速度提升30-50%和成本降低高达70% [6] - 平台支持多种治疗模式 包括小分子、抗体以及PROTACs、分子胶和RNA靶向化合物等新兴疗法 [4] - 平台在广泛靶点包括挑战性靶点上保持持续高成功率 [6] 商业模式与服务范围 - 公司提供从早期基于结构的药物研发到商业化生产的一站式服务 [10] - 技术平台涵盖X射线结晶、冷冻电镜、DEL、ASMS、SPR、HDX、AIDD/CADD等前沿技术 [10] - 通过子公司Langhua Pharma提供从临床前到商业化生产的CMC一站式服务 [10] - 采用服务换股权模式支持高潜力初创公司解决未满足医疗需求 [10] 战略愿景与行业影响 - 公司致力于构建真正整合AI驱动药物发现与基于结构药物发现的平台 [8] - 通过AI驱动建模和基于结构的药物发现加速全球客户决策支持 [7] - 公司投资无缝实验室闭环系统 支持全球客户的首创项目 [7]

格隆汇9月29日｜荷兰制药商Merus(MRUS.US)盘前暴涨超38%，现报95.29美元。此前丹麦生物技术公 司Genmab同意以每股97美元的价格全现金收购Merus，交易价值约为80亿美元。 ...

CLINICAL study SHOWS DETECTION OF CTCs in glioblastoma Patients GBM CTC isolation only possible with Parsortix label-free methodology Data presented at the 7th ACTC meeting GUILDFORD, SURREY / ACCESS Newswire / September 29, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the presentation of new data from a proof-of-concept study in gliobl ...

Denmark's Genmab has agreed to acquire Merus NV , a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said on Monday. ...

Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab ...

Several small- and mid-cap biotech and medical stocks saw notable after-hours price action on Friday, September 26, following a mix of clinical updates, investor presentations, and strategic announcements.Enanta Pharmaceuticals Inc. (ENTA) surged sharply in after-hours trading on Friday, September 26, following a modest gain during the regular session. The stock closed the day at $7.90, up 1.94%, before vaulting another 20% after hours to reach $9.48. This dramatic post-close rally was driven by investor r ...

公司研发进展 - 与多伦多合同研究组织Nucro-Technics Inc合作启动临床前和分析开发服务 [1] - 启动研究性新药(IND)支持计划的首阶段实验室工作 重点开发验证先进分析方法 [1] - 分析方法用于测量独家许可的PNKP抑制剂技术在临床前样本和药物制剂中的含量 [1]

PresentationGood afternoon, and welcome to the United Therapeutics Corporation Phase 3 TETON-2 Results Conference Call. My name is Drew, and I will be your conference operator today. [Operator Instructions] Please note that this call is being recorded. I would now like to turn the webcast over to Harry Silvers, Investor Relations Manager at United Therapeutics.Harrison SilversManager of Investor Relations Thank you, Drew. Good day, everyone. It is my pleasure to welcome you to the United Therapeutics Corpor ...

In this article, we will be taking a look at the 12 Best Performing Healthcare Stocks to Buy Right Now.Spending on healthcare in the US is predicted to hit $5.3 trillion this year, making it one of the largest in the world. Although it is frequently thought of as a defensive industry that fared better in unpredictable times, that has not been the case. Despite the general equities market’s 12% gain so far this year and its rise to record highs, the sector is down roughly 1% for the year.Over the last three ...

Danish biotech Genmab (GMAB) is in advanced discussions to acquire Merus (NASDAQ:MRUS), a Dutch drug developer targeting head and neck cancer, Bloomberg News reported on Sunday, citing people familiar with the matter. Having received takeover interest from several large biopharma ...